Live News EQUITY FLASH L impact Nov 05, 2026, 07:15 AM UTC Acepodia Doses First Patient in Phase 1 ACE723 Trial ACE723 is the first candidate from Acepodia's AD2C platform to enter human testing. SquawkNews Desk